Acutaas Chemicals Limited vs Cohance Lifesciences Limited
An objective side-by-side of ACUTAAS and COHANCE, both in Pharmaceuticals: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-21 close
Latest results: ACUTAAS Jun 2026 · COHANCE Jun 2026
At a glance
- Acutaas Chemicals Limited is the larger company by market value, about 1.6 times the size of Cohance Lifesciences Limited.
- On trailing earnings, Acutaas Chemicals Limited trades at the lower P/E (146.9 against 182.3).
- Over the past year the share prices returned +135.0% (ACUTAAS) and -53.3% (COHANCE).
| Metric | Acutaas Chemicals ACUTAAS |
Cohance Lifesciences COHANCE |
|---|---|---|
| Size and price | ||
| Market cap | ₹28,047 Cr | ₹17,617 Cr |
| Share price | ₹3,426 | ₹460.45 |
| Valuation | ||
| P/E | 146.95 | 182.33 |
| Profitability | ||
| Operating margin | 48.7% | 15.9% |
| Sales (TTM) | ₹843 Cr | ₹2,072 Cr |
| Net profit (TTM) | ₹191 Cr | ₹97 Cr |
| Growth | ||
| Latest quarter sales YoY | +59.1% | -23.1% |
| Latest quarter profit YoY | +70.4% | -197.4% |
| Financial strength | ||
| Interest cover | 122.09 | 6.85 |
| Price performance | ||
| Return 1M | +6.70% | -3.18% |
| Return 3M | +5.42% | +13.62% |
| Return 1Y | +134.96% | -53.27% |
| Return YTD | +100.93% | -12.89% |
| Technical condition | ||
| Technical score | 85 | 62 |
| RS rating (1-99) | 93.00 | 56.00 |
| % vs 200-DMA | +31.65% | +9.42% |
| RSI (14) | 57.47 | 56.79 |
| % from 52-week high | -8.40% | -53.77% |
